204 related articles for article (PubMed ID: 34748872)
1. Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment.
Salmaso S; Mastrotto F; Roverso M; Gandin V; De Martin S; Gabbia D; De Franco M; Vaccarin C; Verona M; Chilin A; Caliceti P; Bogialli S; Marzaro G
J Control Release; 2021 Dec; 340():318-330. PubMed ID: 34748872
[TBL] [Abstract][Full Text] [Related]
2. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
3. Encapsulation of doxorubicin prodrug in heat-triggered liposomes overcomes off-target activation for advanced prostate cancer therapy.
Pereira S; Ma G; Na L; Hudoklin S; Kreft ME; Kostevsek N; Al-Jamal WT
Acta Biomater; 2022 Mar; 140():530-546. PubMed ID: 34954416
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
5. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
6. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J
Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973
[TBL] [Abstract][Full Text] [Related]
7. Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Lv Y; Xu C; Zhao X; Lin C; Yang X; Xin X; Zhang L; Qin C; Han X; Yang L; He W; Yin L
ACS Nano; 2018 Feb; 12(2):1519-1536. PubMed ID: 29350904
[TBL] [Abstract][Full Text] [Related]
8. Selective transfer of a lipophilic prodrug of 5-fluorodeoxyuridine from immunoliposomes to colon cancer cells.
Koning GA; Morselt HW; Velinova MJ; Donga J; Gorter A; Allen TM; Zalipsky S; Kamps JA; Scherphof GL
Biochim Biophys Acta; 1999 Aug; 1420(1-2):153-67. PubMed ID: 10446299
[TBL] [Abstract][Full Text] [Related]
9. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids.
Jensen SS; Andresen TL; Davidsen J; Høyrup P; Shnyder SD; Bibby MC; Gill JH; Jørgensen K
Mol Cancer Ther; 2004 Nov; 3(11):1451-8. PubMed ID: 15542784
[TBL] [Abstract][Full Text] [Related]
10. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.
van Borssum Waalkes M; van Galen M; Morselt H; Sternberg B; Scherphof GL
Biochim Biophys Acta; 1993 May; 1148(1):161-72. PubMed ID: 8499464
[TBL] [Abstract][Full Text] [Related]
11. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics.
Crielaard BJ; van der Wal S; Le HT; Bode AT; Lammers T; Hennink WE; Schiffelers RM; Fens MH; Storm G
Eur J Pharm Sci; 2012 Mar; 45(4):429-35. PubMed ID: 21907797
[TBL] [Abstract][Full Text] [Related]
12. Enhanced in vitro antitumor efficacy of a polyunsaturated fatty acid-conjugated pH-responsive self-assembled ion-pairing liposome-encapsulated prodrug.
Wang Y; Fan P; Zhu L; Zhuang W; Jiang L; Zhang H; Huang H
Nanotechnology; 2020 Apr; 31(15):155101. PubMed ID: 31846941
[TBL] [Abstract][Full Text] [Related]
13. Amphiphilic polyelectrolyte/prodrug nanoparticles constructed by synergetic electrostatic and hydrophobic interactions with cooperative pH-sensitivity for controlled doxorubicin delivery.
Huang P; Wang W; Zhou J; Zhao F; Zhang Y; Liu J; Liu J; Dong A; Kong D; Zhang J
ACS Appl Mater Interfaces; 2015 Mar; 7(11):6340-50. PubMed ID: 25746122
[TBL] [Abstract][Full Text] [Related]
14. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
15. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors.
Fang T; Dong Y; Zhang X; Xie K; Lin L; Wang H
Int J Pharm; 2016 Oct; 512(1):39-48. PubMed ID: 27544846
[TBL] [Abstract][Full Text] [Related]
16. Encapsulation and Controlled Release of a Camptothecin Prodrug from Nanocarriers and Microgels: Tuning Release Rate with Nanocarrier Excipient Composition.
Wilson BK; Sinko PJ; Prud'homme RK
Mol Pharm; 2021 Mar; 18(3):1093-1101. PubMed ID: 33440941
[TBL] [Abstract][Full Text] [Related]
17. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects.
Du Y; Zhang W; He R; Ismail M; Ling L; Yao C; Fu Z; Li X
Bioorg Med Chem; 2017 Jun; 25(12):3247-3258. PubMed ID: 28465086
[TBL] [Abstract][Full Text] [Related]
18. Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts.
Shi L; Wang Y; Wang Q; Jiang Z; Ren L; Yan Y; Liu Z; Wan J; Huang L; Cen B; Han W; Wang H
J Control Release; 2020 Aug; 324():289-302. PubMed ID: 32442582
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.
Amitay Y; Shmeeda H; Patil Y; Gorin J; Tzemach D; Mak L; Ohana P; Gabizon A
Pharm Res; 2016 Mar; 33(3):686-700. PubMed ID: 26572644
[TBL] [Abstract][Full Text] [Related]
20. Phospholipase A(2)-susceptible liposomes of anticancer double lipid-prodrugs.
Arouri A; Mouritsen OG
Eur J Pharm Sci; 2012 Mar; 45(4):408-20. PubMed ID: 21946258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
